BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

219 related articles for article (PubMed ID: 37346070)

  • 1. Role of pancreatic ductal adenocarcinoma risk factors in intraductal papillary mucinous neoplasm progression.
    Gentiluomo M; Corradi C; Arcidiacono PG; Crippa S; Falconi M; Belfiori G; Farinella R; Apadula L; Lauri G; Bina N; Rizzato C; Canzian F; Morelli L; Capurso G; Campa D
    Front Oncol; 2023; 13():1172606. PubMed ID: 37346070
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Smoking Status and the Incidence of Pancreatic Cancer Concomitant With Intraductal Papillary Mucinous Neoplasm.
    Nakagawa T; Masuda A; Toyama H; Shiomi H; Zen Y; Sofue K; Takenaka M; Kobayashi T; Yagi Y; Yamanaka K; Yoshida M; Arisaka Y; Okabe Y; Kutsumi H; Fukumoto T; Ku Y; Azuma T
    Pancreas; 2017 Apr; 46(4):582-588. PubMed ID: 28099253
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Deep sequencing of cancer-related genes revealed GNAS mutations to be associated with intraductal papillary mucinous neoplasms and its main pancreatic duct dilation.
    Takano S; Fukasawa M; Maekawa S; Kadokura M; Miura M; Shindo H; Takahashi E; Sato T; Enomoto N
    PLoS One; 2014; 9(6):e98718. PubMed ID: 24897499
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pancreatic ductal adenocarcinomas associated with intraductal papillary mucinous neoplasms (IPMNs) versus pseudo-IPMNs: relative frequency, clinicopathologic characteristics and differential diagnosis.
    Muraki T; Jang KT; Reid MD; Pehlivanoglu B; Memis B; Basturk O; Mittal P; Kooby D; Maithel SK; Sarmiento JM; Christians K; Tsai S; Evans D; Adsay V
    Mod Pathol; 2022 Jan; 35(1):96-105. PubMed ID: 34518632
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Disease spectrum of intraductal papillary mucinous neoplasm with an associated invasive carcinoma invasive IPMN versus pancreatic ductal adenocarcinoma-associated IPMN.
    Kang MJ; Lee KB; Jang JY; Kwon W; Park JW; Chang YR; Kim SW
    Pancreas; 2013 Nov; 42(8):1267-74. PubMed ID: 24308063
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prognostic impact of para-aortic lymph node status in resected pancreatic ductal adenocarcinoma and invasive intraductal papillary mucinous neoplasm - Time to consider a reclassification?
    Linder S; Holmberg M; Engstrand J; Ghorbani P; Sparrelid E
    Surg Oncol; 2022 May; 41():101735. PubMed ID: 35287096
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Outcome after surgery for invasive intraductal papillary mucinous neoplasia compared to conventional pancreatic ductal adenocarcinoma - A Swedish nationwide register-based study.
    Holmberg M; Radkiewicz C; Strömberg C; Öman M; Ghorbani P; Löhr JM; Sparrelid E
    Pancreatology; 2023 Jan; 23(1):90-97. PubMed ID: 36522260
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Chronic inflammatory changes and oxidative stress in the background of "pancreatic ductal adenocarcinoma concomitant with intraductal papillary mucinous neoplasm".
    Matsuda R; Miyasaka Y; Yamada Y; Kawata J; Sakihama K; Yamamoto T; Saeki K; Yamamoto H; Ohishi Y; Koga Y; Nakamura M; Oda Y
    Virchows Arch; 2020 Dec; 477(6):799-806. PubMed ID: 32468246
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Long-standing diabetes mellitus increases concomitant pancreatic cancer risk in patients with intraductal papillary mucinous neoplasms.
    Yamaguchi A; Tazuma S; Tamaru Y; Kusunoki R; Kuwai T; Kouno H; Toyota N; Sudo T; Kuraoka K; Kohno H
    BMC Gastroenterol; 2022 Dec; 22(1):529. PubMed ID: 36539713
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A polymorphic variant in telomere maintenance is associated with worrisome features and high-risk stigmata development in IPMNs.
    Giaccherini M; Gentiluomo M; Arcidiacono PG; Falconi M; Testoni SGG; Apadula L; Lauri G; Di Franco G; Fatucchi LM; Petrone MC; Corradi C; Crippa S; Morelli L; Capurso G; Campa D
    Carcinogenesis; 2022 Sep; 43(8):728-735. PubMed ID: 35675759
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Functional reprogramming of peripheral blood monocytes by soluble mediators in patients with pancreatic cancer and intraductal papillary mucinous neoplasms.
    Eckhoff AM; Brown MC; Landa K; Naqvi I; Holl EK; Boczkowski D; Fletcher A; Rhodin KE; Giang MH; Sullenger B; Beasley GM; Allen PJ; Nair SK
    Front Immunol; 2023; 14():1116034. PubMed ID: 37575220
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Association between hyperechogenic pancreas and pancreatic ductal adenocarcinoma concomitant with intraductal papillary mucinous neoplasms.
    Mandai K; Uno K; Nakase K; Kawamura T; Yasuda K
    J Med Ultrason (2001); 2019 Oct; 46(4):435-439. PubMed ID: 31069577
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Multifocal cysts and incidence of pancreatic cancer concomitant with intraductal papillary mucinous neoplasm.
    Ikegawa T; Masuda A; Sakai A; Toyama H; Zen Y; Sofue K; Nakagawa T; Shiomi H; Takenaka M; Kobayashi T; Yoshida M; Arisaka Y; Okabe Y; Kutsumi H; Fukumoto T; Azuma T
    Pancreatology; 2018 Jun; 18(4):399-406. PubMed ID: 29685673
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pancreatic ductal adenocarcinoma concomitant with intraductal papillary mucinous neoplasm: a report of 8 cases.
    Mandai K; Uno K; Yasuda K
    Clin J Gastroenterol; 2013 Jun; 6(3):248-54. PubMed ID: 26181604
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Long-term Risk of Malignancy in Branch-Duct Intraductal Papillary Mucinous Neoplasms.
    Oyama H; Tada M; Takagi K; Tateishi K; Hamada T; Nakai Y; Hakuta R; Ijichi H; Ishigaki K; Kanai S; Kogure H; Mizuno S; Saito K; Saito T; Sato T; Suzuki T; Takahara N; Morishita Y; Arita J; Hasegawa K; Tanaka M; Fukayama M; Koike K
    Gastroenterology; 2020 Jan; 158(1):226-237.e5. PubMed ID: 31473224
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Does a family history of pancreatic ductal adenocarcinoma and cyst size influence the follow-up strategy for intraductal papillary mucinous neoplasms of the pancreas?
    Mandai K; Uno K; Yasuda K
    Pancreas; 2014 Aug; 43(6):917-21. PubMed ID: 24743378
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Value of EUS in early detection of pancreatic ductal adenocarcinomas in patients with intraductal papillary mucinous neoplasms.
    Kamata K; Kitano M; Kudo M; Sakamoto H; Kadosaka K; Miyata T; Imai H; Maekawa K; Chikugo T; Kumano M; Hyodo T; Murakami T; Chiba Y; Takeyama Y
    Endoscopy; 2014 Jan; 46(1):22-9. PubMed ID: 24218310
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Loss of Pten and Activation of Kras Synergistically Induce Formation of Intraductal Papillary Mucinous Neoplasia From Pancreatic Ductal Cells in Mice.
    Kopp JL; Dubois CL; Schaeffer DF; Samani A; Taghizadeh F; Cowan RW; Rhim AD; Stiles BL; Valasek M; Sander M
    Gastroenterology; 2018 Apr; 154(5):1509-1523.e5. PubMed ID: 29273451
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Outcome after resection for invasive intraductal papillary mucinous neoplasia is similar to conventional pancreatic ductal adenocarcinoma.
    Holmberg M; Ghorbani P; Gilg S; Del Chiaro M; Arnelo U; Löhr JM; Sparrelid E
    Pancreatology; 2021 Oct; 21(7):1371-1377. PubMed ID: 34426077
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cytopathologic diagnosis of oncocytic type intraductal papillary mucinous neoplasm: Criteria and clinical implications of accurate diagnosis.
    Reid MD; Stallworth CR; Lewis MM; Akkas G; Memis B; Basturk O; Adsay V
    Cancer Cytopathol; 2016 Feb; 124(2):122-34. PubMed ID: 26415076
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.